21:15 , May 18, 2018 |  BioCentury  |  Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
21:29 , Sep 29, 2017 |  BC Week In Review  |  Financial News

Synthace completes series A

Synthace Ltd. (London, U.K.) raised £7.3 million ($9.9 million) on Sept. 19 in a series A round led by Sofinnova Partners and White Cloud Capital. Amadeus Capital Partners and Eleven Two Capital participated in the...
01:15 , Mar 2, 2017 |  BC Week In Review  |  Financial News

Congenica completes venture financing

On Feb. 27, genome analysis company Congenica Ltd. (Hinxton, U.K.) raised £8 million ($9.9 million) in a series B round. Existing investors Cambridge Innovation Capital and Amadeus Capital Partners participated with new investor Parkwalk Advisors....
07:00 , Apr 13, 2015 |  BC Week In Review  |  Financial News

PhoreMost completes venture financing

PhoreMost Ltd. , Cambridge, U.K.   Business: Cancer   Date completed: 2015-04-07   Type: Venture financing   Raised: L2.5 million ($3.7 million)   Investors: Cambridge Angels; Amadeus Capital Partners; o2h Ventures; Cambridge Enterprise; company management...
00:46 , May 25, 2006 |  BC Extra  |  Financial News

U.K. backs high-tech seed funds

The U.K.'s Ministry of Trade and Industry said it will back the creation of two new enterprise capital funds (ECFs) to invest in small- to medium-sized enterprises, which includes U.K. biotechs. ECFs invest a combination...
08:00 , Dec 12, 2005 |  BioCentury  |  Finance

PIPE adventures

PIPE adventures Company Date Raised PIPE price per share 12/9 cls Chg Adolor (ADLR) 5/30/01 $60.0 $20.00 $14.06 -30% Investors in the pain company included The Sprout Group; OrbiMed Advisors; Lombard Odier; and BB Biotech...
00:26 , Jul 13, 2005 |  BC Extra  |  Financial News

Solexa raises $24 million

SLXA raised $24 million through the sale of about 6 million shares at $4 in the second and final closing of a $32.5 million private placement. SG Cowen was the placement agent. Existing investors Abingworth...
07:00 , May 17, 2004 |  BioCentury  |  Finance

Europe's Iceberg III

As European investors continue to put the bulk of their money to work in U.S. companies, Europe's biotech industry needs to figure out what it is about U.S. companies that makes them more attractive. In...
07:00 , Apr 5, 2004 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Solexa Ltd. Cambridge, U.K. Technology: Single molecular array Disease focus: N/A Clinical status: N/A Founded: 1998 by Shankar Balasubramanian and David Klenerman Corporate partners: N/A University collaborators: University of Cambridge, The Sanger Institute Number of...
07:00 , Oct 1, 2001 |  BioCentury  |  Finance

Ebb & Flow

Telik (TELK) sold the first underwritten deal since the terrorist attacks on Sept. 11, raising $26 million through the sale of 4 million shares at $6.50 in a follow-on. However, investors shouldn't read too much...